

PATENT ASSIGNMENT COVER SHEET

Assignment ID: 617834

Electronic Version v1.1

Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT																																
NATURE OF CONVEYANCE:	ASSIGNMENT																																
CONVEYING PARTY DATA																																	
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>Jennifer Pitzen</td><td>01/22/2024</td></tr><tr><td>Maximiliano De La Higuera Macias</td><td>01/23/2024</td></tr><tr><td>Nicole Cooper</td><td>01/22/2024</td></tr><tr><td>Christopher Joseph Sinz</td><td>06/05/2024</td></tr><tr><td>Patrick Sang Tae Lee</td><td>06/05/2024</td></tr><tr><td>Jessica Wahlers</td><td>01/22/2024</td></tr><tr><td>Nathan Fastman</td><td>01/22/2024</td></tr><tr><td>Christos Tzitzilonis</td><td>01/22/2024</td></tr><tr><td>David John Morgans Jr.</td><td>01/23/2024</td></tr><tr><td>Yuxi Liu</td><td>01/22/2024</td></tr><tr><td>Kevin Mellem</td><td>01/22/2024</td></tr><tr><td>Alexander Wayne Schammel</td><td>01/22/2024</td></tr><tr><td>Chris Ziebenhaus</td><td>01/22/2024</td></tr><tr><td>Adam Neil Reid</td><td>01/24/2024</td></tr><tr><td>Caleb Henry Karmel</td><td>01/22/2024</td></tr></tbody></table>	Name	Execution Date	Jennifer Pitzen	01/22/2024	Maximiliano De La Higuera Macias	01/23/2024	Nicole Cooper	01/22/2024	Christopher Joseph Sinz	06/05/2024	Patrick Sang Tae Lee	06/05/2024	Jessica Wahlers	01/22/2024	Nathan Fastman	01/22/2024	Christos Tzitzilonis	01/22/2024	David John Morgans Jr.	01/23/2024	Yuxi Liu	01/22/2024	Kevin Mellem	01/22/2024	Alexander Wayne Schammel	01/22/2024	Chris Ziebenhaus	01/22/2024	Adam Neil Reid	01/24/2024	Caleb Henry Karmel	01/22/2024	
Name	Execution Date																																
Jennifer Pitzen	01/22/2024																																
Maximiliano De La Higuera Macias	01/23/2024																																
Nicole Cooper	01/22/2024																																
Christopher Joseph Sinz	06/05/2024																																
Patrick Sang Tae Lee	06/05/2024																																
Jessica Wahlers	01/22/2024																																
Nathan Fastman	01/22/2024																																
Christos Tzitzilonis	01/22/2024																																
David John Morgans Jr.	01/23/2024																																
Yuxi Liu	01/22/2024																																
Kevin Mellem	01/22/2024																																
Alexander Wayne Schammel	01/22/2024																																
Chris Ziebenhaus	01/22/2024																																
Adam Neil Reid	01/24/2024																																
Caleb Henry Karmel	01/22/2024																																
RECEIVING PARTY DATA																																	
<table border="1"><tr><td>Name:</td><td>Maze Therapeutics, Inc.</td></tr><tr><td>Street Address:</td><td>171 Oyster Point Blvd., Suite 300</td></tr><tr><td>City:</td><td>South San Francisco</td></tr><tr><td>State/Country:</td><td>CALIFORNIA UNITED STATES</td></tr><tr><td>Postal Code:</td><td>94080</td></tr></table>	Name:	Maze Therapeutics, Inc.	Street Address:	171 Oyster Point Blvd., Suite 300	City:	South San Francisco	State/Country:	CALIFORNIA UNITED STATES	Postal Code:	94080																							
Name:	Maze Therapeutics, Inc.																																
Street Address:	171 Oyster Point Blvd., Suite 300																																
City:	South San Francisco																																
State/Country:	CALIFORNIA UNITED STATES																																
Postal Code:	94080																																
PROPERTY NUMBERS Total:2																																	
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>18485224</td></tr><tr><td>PCT Number:</td><td>US2376625</td></tr></tbody></table>	Property Type	Number	Application Number:	18485224	PCT Number:	US2376625																											
Property Type	Number																																
Application Number:	18485224																																
PCT Number:	US2376625																																
CORRESPONDENCE DATA																																	

Fax Number: 6504940792
Phone: (650)813-5600
Email: nmendoza@mofo.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: Mark McBriar
Address Line 1: Morrison & Foerster LLP
Address Line 2: 755 Page Mill Road
Address Line 4: Palo Alto , CALIFORNIA 94304-1018

ATTORNEY DOCKET NUMBER:	79275-20007.00
------------------------------------	----------------

NAME OF SUBMITTER:	Nicole Mendoza
---------------------------	----------------

Signature:	Nicole Mendoza
-------------------	----------------

Date:	11/07/2024
--------------	------------

TOTAL ATTACHMENTS: 1 source= 79275-20007.xx Assignment executed.pdf

ASSIGNMENT

This assignment is by:

- 1 Jennifer Pitzen
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 2 Maximiliano De La Higuera Macias
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 3 Nicole Cooper
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 4 Christopher Joseph Sinz
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 5 Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 6 Jessica Wahlers
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 7 Nathan Fastman
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 8 Christos Tzitzilonis
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America

- 9 David John Morgans, Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 10 Yuxi Liu
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 11 Kevin Mellem
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 12 Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California 94080
United States of America
- 13 Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 14 Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 15 Caleb Henry Karmel
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America

(each referred to in this Assignment as "Assignor"), whose residence or mailing address information is listed above.

This Assignment is to:

Assignee: Maze Therapeutics, Inc.
Address: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under the patent application identified below and the inventions covered thereby.

Assignor invented certain new and useful inventions in:

INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF

which are set forth in:

Serial No.: PCT/US2023/076625

Filing Date: October 11, 2023

Serial No.: 18/485,224

Filing Date: October 11, 2023

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, any and all non-provisionals, divisions, continuations, and continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.
2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said applications for letters patent.
3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) any non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof, or any substitution of any such application, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.
4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR(s):

Date: _____	Signature: _____	Jennifer Pitzen
Date: _____	Signature: _____	Maximiliano De La Higuera Macias
Date: _____	Signature: _____	Nicole Cod
Date: 6/05/24	Signature: _____	Christopher Joseph Sinz
Date: 6/05/24	Signature: _____	Patrick Sang Tae Lee
Date: _____	Signature: _____	Jessica Wahlers
Date: _____	Signature: _____	Nathan Fastman
Date: _____	Signature: _____	Christos Tzitzilonis
Date: _____	Signature: _____	David John Morgans, Jr.
Date: _____	Signature: _____	Yuxi Liu
Date: _____	Signature: _____	Kevin Mellem
Date: _____	Signature: _____	Alexander Wayne Schammel
Date: _____	Signature: _____	Chris Ziebenhaus
Date: _____	Signature: _____	Adam Neil Reid
Date: _____	Signature: _____	Caleb Henry Karmel

ASSIGNEE:

Date: _____	Signature: _____	Name: _____
		Title: _____
		Company: Maze Therapeutics, Inc.

ASSIGNMENT

This assignment is by:

- 1 Jennifer Pitzen
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 2 Maximiliano De La Higuera Macias
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 3 Nicole Cooper
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 4 Christopher Joseph Sinz
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 5 Patrick Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 6 Jessica Wahlers
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 7 Nathan Fastman
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 8 Christos Tzitzilonis
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America

- 9 David John Morgans, Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 10 Yuxi Liu
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 11 Kevin Mellem
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 12 Alexander Wayne Schammel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite 300
South San Francisco, California 94080
United States of America
- 13 Chris Ziebenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 14 Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
- 15 Caleb Henry Karmel
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America

(each referred to in this Assignment as "Assignor"), whose residence or mailing address information is listed above.

This Assignment is to:

Assignee: Maze Therapeutics, Inc.
Address: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
United States of America
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under the patent application identified below and the inventions covered thereby.

Assignor invented certain new and useful inventions in:

INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF

which are set forth in:

Serial No.: PCT/US2023/076625

Filing Date: October 11, 2023

Serial No.: 18/485,224

Filing Date: October 11, 2023

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,









1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, any and all non-provisionals, divisions, continuations, and continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.
2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said applications for letters patent.
3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) any non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof, or any substitution of any such application, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.
4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR(s):

Date: <u>1/22/24</u>	Signature: 	Jennifer Pitzen
Date: <u>1/23/24</u>	Signature: 	Maximiliano De La Higuera Macias
Date: <u>1/22/24</u>	Signature: 	Nicole Cooper
Date: _____	Signature: _____	Christopher Joseph Sinz
Date: _____	Signature: _____	Patrick Sang Tae Lee
Date: <u>1/22/24</u>	Signature: 	Jessica Wahlers
Date: <u>1/22/24</u>	Signature: 	Nathan Fastman
Date: <u>1/22/24</u>	Signature: 	Christos Tzitzilonis
Date: <u>1/23/24</u>	Signature: 	David John Morgans, Jr.
Date: <u>1/22/24</u>	Signature: 	Yuxi Liu
Date: <u>1/22/24</u>	Signature: 	Kevin Mellem
Date: <u>1/22/24</u>	Signature: 	Alexander Wayne Schammel
Date: <u>1/22/24</u>	Signature: 	Chris Ziebenhaus
Date: <u>1/24/24</u>	Signature: 	Adam Neil Reid
Date: <u>1/22/24</u>	Signature: 	Caleb Henry Karmel

ASSIGNEE:

Date: <u>6/05/24</u>	Signature: 	Name: Atul Dandekar Title: CSO Company: Maze Therapeutics, Inc.
----------------------	--	---

TRADUCCIÓN - PORTADA DE CESIÓN DE PATENTES

ID de cesión: 617834

Versión electrónica v1.1 Versión
de la hoja de estilo v1.2

TIPO DE PRESENTACIÓN:	NUEVA CESIÓN
NATURALEZA DE LA TRANSMISIÓN:	CESIÓN

DATOS DE LAS PARTES CEDENTES

Nombre	Fecha de ejecución
Jennifer Pitzen	01/22/2024
Maximiliano De La Higuera Macías	01/23/2024
Nicole Cooper	01/22/2024
Christopher Joseph Sinz	06/05/2024
Patrick Sang Tae Lee	06/05/2024
Jessica Wahlers	01/22/2024
Nathan Fastman	01/22/2024
Christos Tzitzilonis	01/22/2024
David John Morgans Jr.	01/23/2024
Yuxi Liu	01/22/2024
Kevin Mellem	01/22/2024
Alexander Wayne Schammel	01/22/2024
Chris Ziebenhaus	01/22/2024
Adam Neil Reid	01/24/2024
Caleb Henry Karmel	01/22/2024

DATOS DE LA PARTE RECEPTORA

Nombre:	Maze Therapeutics, Inc.
Dirección postal:	171 Oyster Point Blvd., Suite 300
Ciudad:	San Francisco Sur
Estado/País:	CALIFORNIA ESTADOS UNIDOS
Código postal:	94080

NÚMEROS DE PROPIEDAD Total:2

Tipo de propiedad	Número
Número de solicitud:	18485224
Número PCT:	US2376625

DATOS DE CORRESPONDENCIA

Número de fax: 6504940792
Teléfono: (650)813-5600
Correo electrónico: nmendoza@mofo.com
La correspondencia se enviará primero a la dirección de correo electrónico; si no se consigue, se enviará utilizando un número de fax, si se ha facilitado; si no se consigue, se enviará por correo postal.
Nombre del corresponsal: Mark McBriar
Dirección Línea 1: Morrison & Foerster LLP
Dirección Línea 2: 755 Page Mill Road
Dirección Línea 4: Palo Alto , CALIFORNIA 94304-1018

**NÚMERO DE
EXPEDIENTE DEL
ABOGADO:**

79275-20007.00

NOMBRE DEL REMITENTE:

Nicole Mendoza

Firma:

Nicole Mendoza

Date:

11/07/2024

TOTAL DE ARCHIVOS ADJUNTOS: 1

source= 79275-20007.xx Cesión ejecutada.pdf

CESIÓN

Esta cesión es de:

- 1 Jennifer Pitzen
c/o Maze ThempeutiGs, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
- 2 Maxiniiliano De La Higuera Macias
c/o Maze Therapeutics, Inc.
1 71 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
- 3 Nicole Cooper
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
- 4 Christopher Ioseph Sinz c/o
Maze Therapeutics, Inc.
171 Oyster Point Blv't, Suite 300
South San Francisco, California 94080
Estados Unidos de América
- 5 Patricia Sang Tae Lee
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suitt 300
South San Francisco, California 94080
Estados Unidos de América
- G Jessica Walilers
c/o Maze Tlierapeutics, Inc.
171 Oyster' Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
- 7 Nathan Fastinan
c/o Maze Tfierapeutics, Inc.
17 l Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
- 8 Christos Tzifzilonis
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Sviite 300
South San Francisco, California 94080
Estados Unidos de América

- 9 David John Morgans, Jr.
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
- 10 Yuxi Liu
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
- 11 Kevin Mellem
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
- 12 Alexander Wayne Scharmel
c/o Maze Therapeutics, Inc.
171 Oyster Point Boulevard, Suite S00
South San Francisco, California 94080
Estados Unidos de América
- 13 Chris Ziehenhaus
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
- 14 Adam Neil Reid
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
- 15 Caleb Henry Karmel
c/o Maze Therapeutics, Inc.
171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América

(cada uno de ellos denominado en la presente Cesión "Cedente"), cuyos datos de residencia o dirección postal figuran más arriba. La presente Cesión se dirige a:

Cesionario: Maze Therapeutics, Inc.
Dirección: 171 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Estados Unidos de América
Una entidad jurídica debidamente constituida con arreglo a las leyes de: Delaware

(denominado en la presente Cesión "Cesionario"), que desea adquirir la totalidad de los derechos, títulos e intelectos sobre y en virtud de la solicitud de patente que se identifica a continuación y las invenciones cubiertas por la misma.

El cedente inventó ciertas invenciones nuevas y útiles en:

INHIBIDORES DEL MIEMBRO 19 DE LA FAMILIA DE PORTADORES DE SOLUTOS 6A (SLC6A19)
Y MÉTODOS DE USO DE LOS MISMOS
que se establecen en:

Número de serie: PCT/US2023/076625 Fecha de presentación: 11/10/2023

Número de serie: 18/485.224 Fecha de presentación: 11/10/2023

Por buena y onerosa consideración, cuya recepción y suficiencia se reconocen por la presente, y en la medida en que el Cedente no lo haya hecho ya mediante un previo con el Cesionario o un predecesor en interés del Cesionario, o si el Cedente ya lo ha hecho mediante un acuerdo previo con el Cesionario o un predecesor en interés del Cesionario, entonces en confirmación de cualquier obligación de hacerlo en dicho acuerdo previo,

1. Por la presente, el Cedente vende, cede, transfiere y transfiere al Cesionario, sus sucesores, representantes legales y cesionarios, la totalidad de los derechos, títulos e intereses del Cedente sobre las invenciones antes mencionadas, la solicitud de patente, todas y cada una de las solicitudes no provisionales, divisiones, continuaciones y continuaciones en parte que reivindiquen prioridad o el beneficio de las mismas, las sustituciones de dichas solicitudes, y todas y cada una de cartas patentes o patentes en los Estados Unidos de América y en todos los países o jurisdicciones extranjeras que puedan concederse en relación con las mismas, incluyendo, sin limitación, cualquier modificación de dichas cartas patentes o patentes mediante reexpedición, reexamen u otro procedimiento posterior a la concesión, y todas y cada una de las extensiones de dichas cartas patente o patentes, y todos los derechos en virtud del Convenio Internacional para la Protección de la Propiedad Industrial, de los que el Cesionario será titular y gozará (incluido cualquier derecho a ejercitar acciones para recuperar daños y perjuicios por infracciones pasadas, presentes y futuras, y todos y cada uno de los derechos a reivindicar prioridad a dicha solicitud y a todas y cada una de las solicitudes que reivindiquen prioridad a la misma o se basen en dichas invenciones), para su propio uso y el uso de sus sucesores, representantes legales y cesionarios, hasta el final plazo o plazos para los que se puedan conceder las cartas patentes, de forma tan plena y completa como los habría tenido y disfrutado el Cedente, si no se hubiera realizado esta venta y cesión.

2. El Cedente declara, garantiza y acuerda (a) que, en el momento de la ejecución y entrega del presente contrato, el Cedente es el único y legítimo propietario de la totalidad de los derechos, títulos e intereses del Cedente sobre las invenciones derivadas de su condición de inventor y de la solicitud de patente, y que las mismas están libres de cargas y que el Cedente tiene pleno derecho y autoridad legal para seleccionarlas y transmitir las en la forma establecida en el presente contrato, o (b) que el Cedente es el único y legítimo propietario de todos los derechos, títulos e intereses del Cedente sobre dichas invenciones derivadas de su condición de inventor y de dicha solicitud de patente, y que los mismos estaban libres de cargas, ya que el Cedente había vendido, cedido, transferido y traspasado previamente al Cesionario, sus sucesores, representantes legales y cesionarios, o a un predecesor en interés del Cesionario, la totalidad de los derechos, títulos e intereses del Cedente sobre dichas invenciones y dichas solicitudes patente.

3. El Cedente firmará, ejecutará y entregará sin demora al Cesionario todos los papeles, instrumentos, declaraciones juradas y documentos, prestará juramento legal y realizará todos los actos necesarios, requeridos o útiles para la obtención, el mantenimiento, la ejecución, la defensa o, de otro modo, para garantizar la titularidad de los mismos al Cesionario, por cuenta y cargo exclusivos del Cesionario, sus sucesores, representantes legales y cesionarios, en cada caso, incluidos, sin limitación, los derivados de o relacionados con (a) dichas invenciones, o dicha solicitud de patente; (o) cualquier patente o patentes para dichas invenciones en cualquier país o jurisdicción, incluyendo, sin limitación, cualquier modificación de dicha patente o patentes, por ejemplo, mediante reexpedición, reexamen u otro procedimiento posterior a la concesión. A los efectos de este párrafo, "obtención, mantenimiento, ejecución, defensa" incluirá, sin limitación, cualquier preparación, tramitación, procedimiento previo a la concesión y procedimiento posterior a la concesión, ya sea ante una oficina de patentes u otro órgano administrativo o judicial con jurisdicción para ello.

4. Por la presente, el Cedente autoriza y solicita al Comisionado de Patentes de los Estados Unidos de América a transferir las mencionadas patentes de los Estados Unidos de América y cualquier reedición, reexamen, revisión o ampliación de las mismas al Cesionario y en su nombre, como cesionario de dichas invenciones y de las patentes que se expidan sobre las mismas, para el uso exclusivo del Cesionario, sus sucesores, representantes legales y cesionarios.

5. Por la presente, el Cedente otorga a los abogados, todos ellos de Morrison & Foerster LLP (o, en caso necesario, a los abogados del país correspondiente designados y autorizados por Morrison & Foerster LLP), la facultad de insertar en esta cesión cualquier otra identificación que pueda ser necesaria o conveniente para cumplir las normas de la Oficina de Patentes y Marcas de los Estados Unidos o de cualquier autoridad extranjera de expedición de patentes para el registro de este documento, incluida la facultad de insertar en esta cesión el número de solicitud y la fecha de presentación de dicha solicitud cuando se conozcan.

6. Esta cesión puede ser ejecutada en una o más contrapartes, con el mismo efecto que si cada firma estuviera en el mismo documento. Cada una de las contrapartes así ejecutadas se considerará un original, y todas ellas se interpretarán conjuntamente y constituirán un único acuerdo.

En fe de lo cual, firmado por los abajo firmantes en la(s) fecha(s) al lado del(de los) nombre(s) abajo firmante(s).

CEDENTE(S):

Fecha: _____	Firma: _____	Jennifer Pitzen
Fecha: _____	Firma: _____	Maximiliano De La Higuera Macías Nicole
Fecha: _____	Firma: _____	Nicole Cooper
Fecha: _____	Firma: _____	Christopher Joseph Sinz
Fecha: _____	Firma: _____	Patrick Sang Tae Lee Jessica
Fecha: _____	Firma: _____	Jessica Wahlers
Fecha: _____	Firma: _____	Nathan Fastman
Fecha: _____	Firma: _____	Christos Tzitzilonis
Fecha: _____	Firma: _____	David John Morgans, Jr.
Fecha: _____	Firma: _____	Yuxi Liu
Fecha: _____	Firma: _____	Kevin Mellem
Fecha: _____	Firma: _____	Alexander Wayne Schammel
Fecha: _____	Firma: _____	Chris Ziebenhaus
Fecha: _____	Firma: _____	Adam Neil Reid
Fecha: _____	Firma: _____	Caleb Henry Karmel

CESIONARIO:

Fecha: _____	Firma: _____	Nombre: _____
		Título: _____
		Empresa: Maze Therapeutics, Inc.